Product Description: Oseltamivir (GS 4104) is an orally active influenza virus neuraminidase inhibitor (NAI). Oseltamivir inhibits influenza A/H3N2, A/H1N2, A/H1N1, and B viruses with mean IC50s of 0.67, 0.9, 1.34 and 13 nM, respectively[1].
Applications: COVID-19-anti-virus
Formula: C16H28N2O4
Citations: Animal Model Exp Med. 2025 Jan 26./Antiviral Res. 2016 Mar;127:68-78. /bioRxiv. 2024 July 07./Chem Biodivers. 2024 Nov 24:e202402465./Food Funct. 2016 Apr 20;7(4):2052-9. /Int J Infect Dis. 2024 Jun 27:107134./Phytochemistry. 2023 Aug 17;113829./Phytomedicine. 2024 Mar 24, 155534./SSRN. 2024 Aug 7./Virol Sin. 2024 Aug 19:S1995-820X(24)00134-2./Virology. 2023 Dec 2, 109954./Virulence. 2024 Jan 3:2301242./Antiviral Res. 2020 Apr;176:104751. /Arch Pharm Res. 2018 Jun;41(6):664-676./Bioeng Transl Med. 2020 Dec 1;6(1):e10196./Biomed Pharmacother. 2018 Jan;97:385-394. /bioRxiv. 2023 Aug 12./bioRxiv. 2024 May 8:2024.05.06.592815./Biosci Biotechnol Biochem. 2020 Apr;84(4):774-779./Cell Prolif. 2021 Jan;54(1):e12953./Chemosphere. 2015 Jul;131:41-7./Front Cell Dev Biol. 17 December 2021./Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep./Inflammation. 2023 Aug 21./Int J Mol Sci. 2019 Dec 12;20(24):6261./Int J Mol Sci. 2022 Apr 1;23(7):3940./J Ethnopharmacol. 2023 Oct 6:117290./J Med Virol. 2023 Jul;95(7):e28968./Lab Invest. 2020 Dec;100(12):1602-1617./Sci Rep. 2021 Aug 11;11(1):16293./Signal Transduct Target Ther. 2021 Apr 24;6(1):165./Virology. 2020 Jun;545:1-9./Viruses. 2018 Jun 13;10(6). pii: E325.
References: [1]O Ferraris, et al. Sensitivity of Influenza Viruses to Zanamivir and Oseltamivir: A Study Performed on Viruses Circulating in France Prior to the Introduction of Neuraminidase Inhibitors in Clinical Practice. Antiviral Res. 2005 Oct;68(1):43-8./[2]Smee DF, et al. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. Antiviral Res. 2016 Dec;136:45-50. /[3]Ilyushina NA, et al. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther. 2007;12(3):363-70. /[4]Ilyushina NA, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008 Nov;52(11):3889-97. /[5]Smee DF, et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010 Oct;88(1):38-44.
CAS Number: 196618-13-0
Molecular Weight: 312.40
Compound Purity: 99.94
Research Area: Infection; Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Influenza Virus
English
Deutsch
